To the shareholders and followers of International Stem Cell Corporation:
You’ve likely seen stem cells in the news recently, and we’d like to take an opportunity to give you our views on two of the recent announcements.
First, International Stem Cell Corporation announced yesterday earnings for the third quarter 2011. We’ll be hosting a conference call on Thursday, November 17, 2011 at 10:00 AM PST to discuss key developments in the quarter, provide our outlook and answer your questions. Individuals interested in listening to the conference call may do so by dialing 877-407-8033 for domestic callers or 201-689-8033 for international callers, or from the webcast on the investor relations section of the Company’s Web site at www.internationalstemcell.com.
Second, Geron’s decision, announced yesterday, to terminate its stem cell R&D program in no way affects ISCO’s current strategy or developmental activities, nor does it alter our optimism for the potential of stem cells to eventually treat a broad-range of diseases and conditions. While Geron may be reprioritizing programs, we are committed to the course we are on.
Additionally, ISCO will continue its discussions with CIRM regarding possible funding for our truly unique parthenogenesis technology, particularly in light of the $25 million previously earmarked for Geron coming available for other investments.
Thank you for your interest in ISCO. We hope you will join us for the conference call.
Sincerely,
Ken Aldrich
